Navigation Links
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
Date:12/10/2008

done palmitate treatment groups received a 150 mg eq. injection in the deltoid muscle. On day 8 and every 4 weeks for the duration of the trial they received the randomly assigned fixed dose (25, 100 or 150 mg eq.) in the deltoid or gluteal muscle. The primary endpoint of the trial was change in PANSS(c) total score from baseline to endpoint.

The results showed that with the 150 mg eq. initiation dose, patients taking paliperidone palmitate at any of the three doses (25, 100, or 150 mg eq.) had significantly improved symptoms, based on the primary outcome parameter of change in PANSS total scores, compared to patients on placebo (p is less than or equal to 0.034). Symptoms improved with increased dosage, with those taking the 150 mg eq. dose showing the greatest improvement. Overall treatment-emergent adverse events (TEAEs) occurred at similar rates among the paliperidone palmitate (60-63%) and placebo (65%) groups. The number of patients who reported serious TEAEs was higher in the placebo group (14%) than in any of the paliperidone palmitate groups (25 mg eq. 9.4%; 100 mg eq. 13.3%; 150 mg eq. 8.0%). Common TEAEs occurring greater than or equal to 2% more frequently in the total paliperidone palmitate group compared to the placebo group were injection site pain (placebo, 3.7% vs 7.6% with paliperidone palmitate), dizziness (placebo 1.2% vs 2.5% with paliperidone palmitate), sedation (placebo 0.6% vs 2.3% with paliperidone palmitate), pain in extremity (placebo 0% vs 1.6% with paliperidone palmitate) and myalgia (placebo 0% vs 1.0% with paliperidone palmitate). The overall safety profile was similar to previously published studies of paliperidone ER in the treatment of schizophrenia(1,2).

The authors concluded that using a 150 mg eq. deltoid initiation dose followed by subsequent injections every 4 weeks of 25-150 mg eq. of paliperidone palmitate produced statistically significant symptom control as measured by the P
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. SemBioSys begins phase I/II trial of insulin produced in plant seeds
10. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
11. OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... , Sept. 15, 2014 Zymo ... viral transport solution for safe ambient temperature storage ... molecular testing. Importantly, the infectivity of agents in such ... maintaining the integrity of the viral nucleic acids ... the recent Ebola epidemic in West ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3
... Dr. ... San Antonio and South Central Texas, , ... (PRWEB) June 15, 2010 -- For those looking for a trimmer physique without ... Zeltiq ™ Procedure, a new non-invasive body contouring procedure, at his practice - Advanced ...
... data from a retrospective cohort study showed that up to three quarters ... have a substantial adverse effect on major PD-related clinical and health economic ... Disease and Movement Disorders in Buenos Aires, Argentina ( June ... , "The ...
... leading publication on diversity and business, has recognized University Hospitals as a leader among ... , , ... Companies for Diversity based on results from an extensive questionnaire. This is the first ... , , ...
Cached Biology Technology:Dr. Suresh Koneru Introduces Zeltiq Non-Invasive Procedure For Fat Reduction 2Dr. Suresh Koneru Introduces Zeltiq Non-Invasive Procedure For Fat Reduction 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 2New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 4Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation 2
(Date:9/15/2014)... 2014) The so-called central dogma of molecular ... provided a simplified explanation for how genetic information ... , In reality, of course, the process is ... nearly 60 years ago by Nobel Laureate Francis ... one, there are multiple types of RNA, three ...
(Date:9/15/2014)... a simple, mechanical solution to avoid chromosome sorting ... Science Express. , This natural ... lead to infertility, miscarriage, or congenital conditions. ... problems, but what exactly goes wrong is often ... Trust Center for Cell Biology at the University ...
(Date:9/15/2014)... that a single group of microorganisms may be responsible ... the oceans, with implications for the global carbon cycle ... essential molecule required by most life on this planet, ... of microorganisms because it is so large and complex. ... maintaining the brain and nervous systems, as well as ...
Breaking Biology News(10 mins):Scientists discover RNA modifications in some unexpected places 2Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3Researchers discover new producer of crucial vitamin 2
... University of North Carolina at Chapel Hill has received ... & Melinda Gates Foundation. The grant will support ... Tsuruta, PhD, and Paul Dayton, PhD, titled "Ultrasound as ... professor in the Laboratories for Reproductive Biology in UNC,s ...
... It has been a hard winter for Monarch butterflies, according ... of Kansas. Taylor said that low temperatures, storms and habitat ... "I spend a lot of time fretting over ... for factors or data that will help me understand the ...
... team of researchers led by University of Notre Dame ... thinking about the genomics of speciation. Titled "Widespread genomic ... edition of the Proceedings of the National Academy ... how the genomes of newly forming species should differ ...
Cached Biology News:UNC researchers receive $100,000 Grand Challenges Exploration Grant to develop male contraceptive 2As monarch butterflies journey north, gardeners can help protect species, researcher says 2Paper offers new insights into the genomics of speciation 2
Spastin (Sp 3G11/1)...
mCD-1 10 transcription reactions...
... Rabbits x 2 , ... bleed x1 /each , Immunizations/Boost injections ... (app. 5 ml) x1 /each , ... /each , Final Bleed ~ 100 ml blood ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
Biology Products: